These data suggest that targeting the PD-1/PD-L1 pathway may be an effective strategy for eliminating CML cells [249], and treatment with ICIs could potentially increase immunoreactivity against leukemic cells in CML [4]. This evidence concerns the gene CD274 and chronic myelogenous leukemia, BCR-ABL1 positive.